Evaluation of the Friend Virus model for the development of improved adenovirus-vectored anti-retroviral vaccination strategies

Vaccine

Volumn 26, Issue 5, 2008, Pages 716-726

  Bayer, Wibke ^a   Schimmer, Simone ^b   Hoffmann, Dennis ^a   Dittmer, Ulf ^b   Wildner, Oliver ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Friend Virus; Human adenovirus vectors; Vaccination

Indexed keywords

ADENOVIRUS VECTOR; GAG PROTEIN; VIRUS VACCINE;

ARTICLE; CONTROLLED STUDY; FRIEND LEUKEMIA VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; RETROVIRUS INFECTION; T LYMPHOCYTE; VACCINATION;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; ANTIBODIES, VIRAL; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; FRIEND MURINE LEUKEMIA VIRUS; GENES, ENV; GENES, GAG; GENETIC VECTORS; HUMANS; IMMUNIZATION SCHEDULE; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED C57BL; NEUTRALIZATION TESTS; REASSORTANT VIRUSES; RETROVIRIDAE INFECTIONS; SPECIES SPECIFICITY; SPLEEN; T-LYMPHOCYTES; TUMOR VIRUS INFECTIONS; VACCINATION; VACCINES, DNA;

EID: 37849045128     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.11.050     Document Type: Article

References (65)

1. Letvin N.L. Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol 6 December (12) (2006) 930-939
2. Girard M.P., Osmanov S.K., and Kieny M.P. A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine 24 May (19) (2006) 4062-4081
3. Singh M. No vaccine against HIV yet-are we not perfectly equipped?. Virol J 3 (2006) 60
4. Dias A.S., Bester M.J., Britz R.F., and Apostolides Z. Animal models used for the evaluation of antiretroviral therapies. Curr HIV Res 4 October (4) (2006) 431-446
5. Lackner A.A., and Veazey R.S. Current concepts in AIDS pathogenesis: insights from the SIV/macaque model. Annu Rev Med 58 (2007) 461-476
6. Hasenkrug K.J., and Chesebro B. Immunity to retroviral infection: the Friend virus model. Proc Natl Acad Sci USA 94 July (15) (1997) 7811-7816
7. Kabat D. Molecular biology of Friend viral erythroleukemia. Curr Top Microbiol Immunol 148 (1989) 1-42
8. Friend C. Cell-free transmission in adult Swiss mice of a disease having the character of a leukemia. J Exp Med 105 April (4) (1957) 307-318
9. Robertson M.N., Spangrude G.J., Hasenkrug K., Perry L., Nishio J., Wehrly K., et al. Role and specificity of T-cell subsets in spontaneous recovery from Friend virus-induced leukemia in mice. J Virol 66 June (6) (1992) 3271-3277
10. Hasenkrug K.J., Brooks D.M., and Chesebro B. Passive immunotherapy for retroviral disease: influence of major histocompatibility complex type and T-cell responsiveness. Proc Natl Acad Sci USA 92 November (23) (1995) 10492-10495
11. Lilly F. Fv-2: identification and location of a second gene governing the spleen focus response to Friend leukemia virus in mice. J Natl Cancer Inst 45 July (1) (1970) 163-169
12. Pincus T., Rowe W.P., and Lilly F. A major genetic locus affecting resistance to infection with murine leukemia viruses. II. Apparent identity to a major locus described for resistance to friend murine leukemia virus. J Exp Med 133 June (6) (1971) 1234-1241
13. Lilly F. The effect of histocompatibility-2 type on response to friend leukemia virus in mice. J Exp Med 127 March (3) (1968) 465-473
14. Hasenkrug K.J., Brooks D.M., and Dittmer U. Critical role for CD4(+) T cells in controlling retrovirus replication and spread in persistently infected mice. J Virol 72 August (8) (1998) 6559-6564
15. Aandahl E.M., Michaelsson J., Moretto W.J., Hecht F.M., and Nixon D.F. Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol 78 March (5) (2004) 2454-2459
16. Zelinskyy G., Robertson S.J., Schimmer S., Messer R.J., Hasenkrug K.J., and Dittmer U. CD8+ T-cell dysfunction due to cytolytic granule deficiency in persistent Friend retrovirus infection. J Virol 79 August (16) (2005) 10619-10626
17. Hasenkrug K.J., Brooks D.M., Robertson M.N., Srinivas R.V., and Chesebro B. Immunoprotective determinants in friend murine leukemia virus envelope protein. Virology 248 August (1) (1998) 66-73
18. Hunsmann G., Schneider J., and Schulz A. Immunoprevention of Friend virus-induced erythroleukemia by vaccination with viral envelope glycoprotein complexes. Virology 113 September (2) (1981) 602-612
19. Iwanami N., Niwa A., Yasutomi Y., Tabata N., and Miyazawa M. Role of natural killer cells in resistance against friend retrovirus-induced leukemia. J Virol 75 April (7) (2001) 3152-3163
20. Kleiser C., Schneider J., Bayer H., and Hunsmann G. Immunoprevention of Friend leukaemia virus-induced erythroleukaemia by vaccination with aggregated gp70. J Gen Virol 67 September (Pt 9) (1986) 1901-1907
21. Miyazawa M., Nishio J., and Chesebro B. Protection against Friend retrovirus-induced leukemia by recombinant vaccinia viruses expressing the gag gene. J Virol 66 July (7) (1992) 4497-4507
22. Dittmer U., Brooks D.M., and Hasenkrug K.J. Characterization of a live-attenuated retroviral vaccine demonstrates protection via immune mechanisms. J Virol 72 August (8) (1998) 6554-6558
23. Earl P.L., Moss B., Morrison R.P., Wehrly K., Nishio J., and Chesebro B. T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant. Science 234 November (4777) (1986) 728-731
24. Dittmer U., Brooks D.M., and Hasenkrug K.J. Protection against establishment of retroviral persistence by vaccination with a live attenuated virus. J Virol 73 May (5) (1999) 3753-3757
25. Ruan K.S., and Lilly F. Approach to a retrovirus vaccine: immunization of mice against Friend virus disease with a replication-defective Friend murine leukemia virus. Proc Natl Acad Sci USA 89 December (24) (1992) 12202-12206
26. Shiver J.W., and Emini E.A. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 55 (2004) 355-372
27. Ahlers J.D., Dunlop N., Alling D.W., Nara P.L., and Berzofsky J.A. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. J Immunol 158 April (8) (1997) 3947-3958
28. Ahlers J.D., Belyakov I.M., Matsui S., and Berzofsky J.A. Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. Int Immunol 13 July (7) (2001) 897-908
29. Bolesta E., Kowalczyk A., Wierzbicki A., Eppolito C., Kaneko Y., Takiguchi M., et al. Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery. J Immunol 177 July (1) (2006) 177-191
30. Song R., Liu S., Adams R.J., and Leong K.W. Enhancing efficacy of HIV gag DNA vaccine by local delivery of GM-CSF in murine and macaque models. J Interferon Cytokine Res 26 June (6) (2006) 380-389
31. He T.C., Zhou S., da Costa L.T., Yu J., Kinzler K.W., and Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95 March (5) (1998) 2509-2514
32. Nilsson M., Ljungberg J., Richter J., Kiefer T., Magnusson M., Lieber A., et al. Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells. J Gene Med 6 June (6) (2004) 631-641
33. Grimm E.A., Jacobs S.K., Lanza L.A., Melin G., Roth J.A., and Wilson D.J. Interleukin 2-activated cytotoxic lymphocytes in cancer therapy. Symp Fundam Cancer Res 38 (1986) 209-219
34. Leimig T., Brenner M., Ramsey J., Vanin E., Blaese M., and Dilloo D. High-efficiency transduction of freshly isolated human tumor cells using adenoviral interleukin-2 vectors. Hum Gene Ther 7 June (10) (1996) 1233-1239
35. Morris J.C., and Wildner O. Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk. Mol Ther 1 January (1) (2000) 56-62
36. Shi F., Rakhmilevich A.L., Heise C.P., Oshikawa K., Sondel P.M., Yang N.S., et al. Intratumoral injection of interleukin-12 plasmid DNA, either naked or in complex with cationic lipid, results in similar tumor regression in a murine model. Mol Cancer Ther 1 September (11) (2002) 949-957
37. Kremer L., Dupre L., Wolowczuk I., and Locht C. In vivo immunomodulation following intradermal injection with DNA encoding IL-18. J Immunol 163 September (6) (1999) 3226-3231
38. Mittereder N., March K.L., and Trapnell B.C. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 70 November (11) (1996) 7498-7509
39. Chesebro B., Wehrly K., and Stimpfling J. Host genetic control of recovery from Friend leukemia virus-induced splenomegaly: mapping of a gene within the major histocompatability complex. J Exp Med 140 December (6) (1974) 1457-1467
40. Robertson M.N., Miyazawa M., Mori S., Caughey B., Evans L.H., Hayes S.F., et al. Production of monoclonal antibodies reactive with a denatured form of the Friend murine leukemia virus gp70 envelope protein: use in a focal infectivity assay, immunohistochemical studies, electron microscopy and western blotting. J Virol Methods 34 October (3) (1991) 255-271
41. Dittmer U., He H., Messer R.J., Schimmer S., Olbrich A.R., Ohlen C., et al. Functional impairment of CD8(+) T cells by regulatory T cells during persistent retroviral infection. Immunity 20 March (3) (2004) 293-303
42. Schepers K., Toebes M., Sotthewes G., Vyth-Dreese F.A., Dellemijn T.A., Melief C.J., et al. Differential kinetics of antigen-specific CD4+ and CD8+ T cell responses in the regression of retrovirus-induced sarcomas. J Immunol 169 September (6) (2002) 3191-3199
43. Iwashiro M., Kondo T., Shimizu T., Yamagishi H., Takahashi K., Matsubayashi Y., et al. Multiplicity of virus-encoded helper T-cell epitopes expressed on FBL-3 tumor cells. J Virol 67 August (8) (1993) 4533-4542
44. Lutz M.B., Kukutsch N., Ogilvie A.L., Rossner S., Koch F., Romani N., et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223 February (1) (1999) 77-92
45. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5 March (3) (2004) 233-236
46. Cohen J. AIDS research. Promising AIDS vaccine's failure leaves field reeling. Science 318 October (5847) (2007) 28-29
47. Kuroda M.J., Schmitz J.E., Charini W.A., Nickerson C.E., Lifton M.A., Lord C.I., et al. Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. J Immunol 162 May (9) (1999) 5127-5133
48. Borrow P., Lewicki H., Hahn B.H., Shaw G.M., and Oldstone M.B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68 September (9) (1994) 6103-6110
49. Harrer T., Harrer E., Kalams S.A., Barbosa P., Trocha A., Johnson R.P., et al. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J Immunol 156 April (7) (1996) 2616-2623
50. Santra S., Seaman M.S., Xu L., Barouch D.H., Lord C.I., Lifton M.A., et al. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol 79 May (10) (2005) 6516-6522
51. Suh Y.S., Park K.S., Sauermann U., Franz M., Norley S., Wilfingseder D., et al. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model. Vaccine 24 March (11) (2006) 1811-1820
52. Natuk R.J., Lubeck M.D., Chanda P.K., Chengalvala M., Wade M.S., Murthy S.C., et al. Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees. AIDS Res Hum Retroviruses 9 May (5) (1993) 395-404
53. Barratt-Boyes S.M., Soloff A.C., Gao W., Nwanegbo E., Liu X., Rajakumar P.A., et al. Broad cellular immunity with robust memory responses to simian immunodeficiency virus following serial vaccination with adenovirus 5- and 35-based vectors. J Gen Virol 87 January (Pt 1) (2006) 139-149
54. Wu L., Kong W.P., and Nabel G.J. Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens. J Virol 79 July (13) (2005) 8024-8031
55. Lemckert A.A., Sumida S.M., Holterman L., Vogels R., Truitt D.M., Lynch D.M., et al. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol 79 August (15) (2005) 9694-9701
56. Barouch D.H., Pau M.G., Custers J.H., Koudstaal W., Kostense S., Havenga M.J., et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 172 May (10) (2004) 6290-6297
57. Thorner A.R., Lemckert A.A., Goudsmit J., Lynch D.M., Ewald B.A., Denholtz M., et al. Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity. J Virol 80 December (24) (2006) 12009-12016
58. Messer R.J., Dittmer U., Peterson K.E., and Hasenkrug K.J. Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection. Proc Natl Acad Sci USA 101 August (33) (2004) 12260-12265
59. Kawabata H., Niwa A., Tsuji-Kawahara S., Uenishi H., Iwanami N., Matsukuma H., et al. Peptide-induced immune protection of CD8+ T cell-deficient mice against Friend retrovirus-induced disease. Int Immunol 18 January (1) (2006) 183-198
60. Sugahara D., Tsuji-Kawahara S., and Miyazawa M. Identification of a protective CD4+ T-cell epitope in p15gag of Friend murine leukemia virus and role of the MA protein targeting the plasma membrane in immunogenicity. J Virol 78 June (12) (2004) 6322-6334
61. Buge S.L., Murty L., Arora K., Kalyanaraman V.S., Markham P.D., Richardson E.S., et al. Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251. J Virol 73 September (9) (1999) 7430-7440
62. Rasmussen R.A., Ong H., Song R., Chenine A.L., Ayash-Rashkovsky M., Hu S.L., et al. Efficacy of a multigenic protein vaccine containing multimeric HIV gp160 against heterologous SHIV clade C challenges. AIDS 21 September (14) (2007) 1841-1848
63. Zhang P.F., Cham F., Dong M., Choudhary A., Bouma P., Zhang Z., et al. Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proc Natl Acad Sci USA 104 June (24) (2007) 10193-10198
64. Muruve D.A., Barnes M.J., Stillman I.E., and Libermann T.A. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther 10 April (6) (1999) 965-976
65. Higginbotham J.N., Seth P., Blaese R.M., and Ramsey W.J. The release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro following exposure to adenovirus variants and capsid. Hum Gene Ther 13 January (1) (2002) 129-141